A carregar...

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens

SIMPLE SUMMARY: Neoadjuvant chemotherapy strategy (NAC) is a standard of care for Human Epidermal Growth Factor Receptor-2 (HER2)-positive early breast cancer but there is no proven beneficial evidence in terms of survival compared to the adjuvant chemotherapy strategy. Our retrospective study found...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Laas, Enora, Bresset, Arnaud, Féron, Jean-Guillaume, Le Gal, Claire, Darrigues, Lauren, Coussy, Florence, Grandal, Beatriz, Laot, Lucie, Pierga, Jean-Yves, Reyal, Fabien, Hamy, Anne-Sophie
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2021
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7864202/
https://ncbi.nlm.nih.gov/pubmed/33498405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13030370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!